Serina Therapeutics appoints Trevi CCO Farrell Simon to board

Serina Therapeutics Inc
Trevi Therapeutics

Serina Therapeutics Inc

SER

0.00

Trevi Therapeutics

TRVI

0.00
  • Serina Therapeutics named Farrell Simon to its board, effective immediately.
  • Simon will join the audit committee, plus the compensation committee.
  • He is chief commercial officer at Trevi Therapeutics, leading commercial strategy, lifecycle management, pre-launch planning, business development.
  • Previously held senior commercial, strategic leadership roles at Pfizer, including Biopharma chief of staff.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607221630PRIMZONEFULLFEED9766427) on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.